Dihydroberberine (DHB)
Dihydroberberine (GlucoVantage) · also known as Dihydroberberine, DHB, GlucoVantage, Reduced berberine
Dihydroberberine is the reduced form of berberine. After oral intake it can be converted to berberine in the body and raise plasma berberine exposure. Human pharmacokinetic studies have very small samples, and AMPK activation in humans has not been directly shown.
Clinical uses and human evidence
Blood sugar and insulin resistance
Mechanisms of action
mTORC1 allosteric inhibition and macroautophagy induction
In some mouse models, dihydroberberine can affect mTOR-related signaling, for example the Rheb/mTOR pathway in an ovarian insufficiency model. These results do not directly show that mTORC1 is blocked in humans at usual oral doses, and they do not show that autophagy flux increases.
Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair
In mouse colitis models, dihydroberberine can raise tight junction proteins and mucin-related markers. Local exposure in the gut makes this result biologically plausible. However, there is no direct human evidence for the same mechanism, and neither ileal ZO-1 upregulation nor a microbiota-mediated pathway has been confirmed.
AMPK sensing of cellular energy deficit and metabolic reprogramming
In isolated mitochondria experiments, dihydroberberine can affect respiration, and animal studies of berberine also show pathway changes. However, these results do not directly show that oral dihydroberberine activates AMPK in humans, and it is unclear whether the required concentrations can be reached.
References (2)
- Turner et al. 2008 · Cell, isolated mitochondria and rodent study: dihydroberberine affected respiration in isolated mitochondria; animal metabolic outcomes alone cannot prove AMPK activation in vivo
- 2022 · Human pharmacokinetic crossover study: only 5 participants per treatment; dihydroberberine raised plasma berberine exposure; human AMPK was not measured
Safety and drug interactions
Low blood sugar risk
Works the same way as berberine. Each of these may lower blood sugar. Taken together, especially on an empty stomach or alongside antidiabetic drugs, they may cause low blood sugar symptoms such as palpitations, shaking and cold sweats.
Inhibition of drug metabolism (CYP3A4 and others)
Same as berberine. Each of these can inhibit the liver enzymes that metabolize drugs (mainly CYP3A4) or drug transporter proteins, raising blood levels of some prescription drugs.
With Digoxin Needs attention
Dihydroberberine is a derivative of berberine and may have similar effects, but there are no direct human studies. If the two are taken together, digoxin levels should be monitored.